pembrolizumab,docetaxel
merck
['biomarker', 'neopact', 'tnbc']
#asco23 reasons why we should learn from the neopact trial: inclusion of tnbc pts defined with a 10% cutoff of hr solid biomarker platform generating highly appealing hypotheses academic study
Ricercatore Oncologia Medica - Oncology Fellow, University of Padova